Trinité-Sur-Mer Celebrates the Launch of the Class40 IBSA
12.9.2022 13:00:00 EEST | Business Wire | Press release
A real celebration was held on September 9 in the port of La Trinité-Sur-Mer, in Brittany, for the launch of the Class40 IBSA , the brand new boat with which Alberto Bona will participate in the Route du Rhum . The transatlantic regatta is indeed the first project of the three-year program Sailing into the Future. Together that the ocean sailor started with IBSA at the beginning of 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220908006032/en/
Class40 IBSA: official launch. From left to right: Sidney Gavignet, Alberto Bona, Arturo Licenziati, Giorgio Pisani, Fabrice Jover (Photo: © IBSA | Beppe Raso)
Great enthusiasm and emotion characterised the event, that took place in the small but famous Breton port, along whose mooring quays are berthed some of the most prestigious trimarans that have gone around the world and have made the history of ocean sailing. And right here, Arturo Licenziati – President and CEO of the IBSA Group – Alberto Bona and his entire team celebrated the launch of an innovative and revolutionary hull, as well as the visionary project that supports it.
“Sailing into the Future. Together is the three-year international project that we strongly pursued, because it combines several elements that for us are extremely important and distinctive: innovation, technology, commitment to sport and to the community, environmental and social responsibility”, commented Arturo Licenziati. “The whole project and this first great sporting challenge that we are preparing to face give us the opportunity to introduce to the world our vision, values and Pillars (Person, Innovation, Quality and Responsibility), the same ones that we share with sport, and with sailing in particular.”
To break the bottle on the hull – in one of the most traditional rites of the nautical world, which officially baptises the boat – will be the godmother Francesca Licenziati, niece of IBSA’s President. The launch celebration is a moment of great pride and joy, shared by the whole team, who for months worked hard on the new boat and collaborated on several fronts, concretely showing how Sailing into the Future. Together is an international project, which involves Switzerland, France and Italy in particular, and is based on strong values of inclusiveness, sustainability and teamwork.
After the technical launch on August 3, the hull designed by Sam Manuard – built by the shipyard JPS Production and hoisting the burgee of the Bellano Yacht Club – has been subject to a series of tests at sea, which allowed Alberto Bona to qualify for the Route du Rhum by sailing, between August 30 and September 5, the first 1,200 miles alone. The navigation took place in the Bay of Biscay, between Brittany and Spain, and highlighted the qualities of the hull and an excellent state of preparation in even complex weather conditions, with the winds and waves typical of the Atlantic Ocean.
“After the technical launch”, said Alberto Bona, “we had very good feedback from every perspective, from the construction of the hull to the sails, from the design to the preparation of the team. We worked to prepare the Class40 IBSA as best, and by the end of August we were ready for the qualification: on this front, we accelerated as much as possible, because after a very hot and dry summer, we had signs that the weather conditions in the Northeast Atlantic were rapidly changing.”
The Class40 IBSA thus already arrived at its launch with over 1,200 miles at sea and the first, exciting occasion of solitary navigation by Alberto Bona.
“These have been even more beautiful days than I could have imagined: on the one hand the satisfaction of now being in perfect timing for the Route du Rhum, considering that we only started the project last February; on the other the certainty of having a reliable and fast boat, the two characteristics that navigators always look for when they have to leave for a challenge like the one that awaits us from November 6, as well as all those to follow.”
“We are very satisfied with the results we have achieved so far. After many months of commitment and hard work, we have finally put into the water a boat that has all the credentials to ensure a very high performance and to be highly competitive”, commented Giorgio Pisani, Vice President Southern Europe IBSA and Project Leader. “The Class40 IBSA is the result of an approach that represents our way of being: it brings together innovation, attention to detail, continuous improvement and determination, with a vision that for IBSA always goes beyond the pharmaceutical field and beyond care.”
With this launch, the countdown to the start of the Route du Rhum has officially begun: in the coming days Alberto Bona and the team will continue working on the boat and will begin a series of targeted training sessions, in some cases working together with other teams registered in the regatta, in a series of joint tests. In mid-September, Bona will participate in the Malouine Lamotte regatta and then, on September 22, he will attend the opening day of the Genoa Boat Show, with the aim of promoting the project Sailing into the Future. Together in all its aspects, in particular that related to social inclusion.
Indeed, in its sailing programme IBSA is also committed in the field of inclusive sailing, with the involvement of prestigious yacht clubs: the Associazione Velabili, based at the Circolo Velico Lago di Lugano (Switzerland); the Société des Régates d’Antibes (France); and the Yacht Club Punta Ala (Italy). The project – which aims to support inclusive sailing, by promoting initiatives that engage people with disabilities in experiences in contact with the sea and the world of sailing – consists in supporting a team of disabled sailors in participating in the Special Olympics World Games of 2023 and in the purchase of Hansa 303 boats for the Clubs of Punta Ala and Antibes.
IBSA
IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company’s 17 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 800 million CHF, and employs over 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220908006032/en/
Contact information
FOR INFORMATION TO THE PRESS
IBSA Press Office – Italy
Martina Baldazzi –
martina.baldazzi@noesis.net – mob: +39 339 222 9911
Valeria Riccobono – valeria.riccobono@noesis.net – mob: +39 392 9625892
Ornella Reccia – ornella.reccia@noesis.net – mob: +39 329 393 1922
IBSA Press Office – Switzerland
Francesca Rossini – notizie@laboratoriodelleparole.net – mob: +41 77 417 93 72
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Present New Data on ALYFTREK ® at the North American Cystic Fibrosis Conference9.10.2026 20:15:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine pancreatic function represent a profound shift in how we understand the benefits of treating cystic fibrosis in its earliest stages,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Devel
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 17:00:00 EEST | Press release
Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Stable Outlook from Fitch Ratings, assigned on 12 June 2026. Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation of the company’s
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 16:17:00 EEST | Press release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magic Quadrant confirms the shift has moved from pilot to boardroom priority. According to Gartner, Visionaries "understands where the market
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 16:15:00 EEST | Press release
Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The valve features the company’s FREE next generation tissue treatment addressing the two main causes of calcification, phospholipids and aldehydes. Its proprietary LANCELOT advanced manufacturing process includes zero-pressure shaping and laser cutting of
Ada earns AWS Travel and Hospitality Competency for resolving traveler issues at scale9.10.2026 16:00:00 EEST | Press release
Ada, the pioneer in Agentic Customer Experience, today announced it has achieved the Amazon Web Services (AWS) Travel and Hospitality Competency. The designation recognizes Ada as an AWS Partner with demonstrated technical proficiency and proven customer success helping travel and hospitality brands resolve customer issues at scale. Ada joins a select group of 58 AWS Partners holding the competency, and it reflects a shared commitment to helping travel brands deliver service that holds up on their busiest, most unpredictable days. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009673638/en/ Ada earns AWS Travel and Hospitality Competency for resolving traveler issues at scale "Travel is where agentic customer service gets tested hardest. Demand spikes without warning, policies change by the hour, and customers are often stressed and far from home," said Mike Murchison, CEO and co-founder of Ada. "Our airline and hospitali
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
